Literature DB >> 8875465

Cyclin D1 in astrocytic tumours: an immunohistochemical study.

A Chakrabarty1, L R Bridges, S Gray.   

Abstract

Forty-eight astrocytic tumours were stained immunohistochemically with antibodies to the cell cycle-regulating protein, cyclin D1, and to the proliferation marker MIB1 (Ki-67) using formalin fixed paraffin embedded tissue and a microwave antigen retrieval system. Cases were classified by the WHO system (1993). The labelling indices (LI) for both antibodies were compared with each other and with the tumour type. The mean labelling indices for both antibodies increased with the degree of malignancy, and a significant difference was seen between the pilocytic astrocytoma and diffuse astrocytoma together vs anaplastic astrocytoma and glioblastoma together. However, within each tumour type there was considerable variation in the labelling indices and a clear cut off value could not be demonstrated. There was a strong positive correlation between labelling indices for cyclin D1 and MIB1 in diffuse astrocytoma, but this correlation broke down increasingly in anaplastic astrocytoma and glioblastoma. There was poor correlation between cyclin D1 and MIB1 in pilocytic astrocytoma, a feature which appeared to separate them from the diffuse astrocytoma. Average labelling indices for cyclin D1 were higher than those of MIB1, which suggests that cyclin D1 positive cells represent a pool of cells from which proliferation and hence MIB1 expression can take place. In conclusion, cyclin D1 is overexpressed in astrocytic tumours, more so with increasing grade of malignancy and in a way which approximately correlates with MIB1 expression.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8875465     DOI: 10.1111/j.1365-2990.1996.tb01109.x

Source DB:  PubMed          Journal:  Neuropathol Appl Neurobiol        ISSN: 0305-1846            Impact factor:   8.090


  6 in total

1.  Knockdown of cyclin D1 inhibits proliferation, induces apoptosis, and attenuates the invasive capacity of human glioblastoma cells.

Authors:  Junyu Wang; Qi Wang; Yong Cui; Zhen Yang Liu; Wei Zhao; Chun Lin Wang; Yan Dong; Lijun Hou; Guohan Hu; Chun Luo; Juxiang Chen; Yicheng Lu
Journal:  J Neurooncol       Date:  2011-09-13       Impact factor: 4.130

2.  Eukaryotic initiation factors (eIF) 2alpha and 4E expression, localization, and phosphorylation in brain tumors.

Authors:  Sonia Tejada; M Val T Lobo; Mercedes García-Villanueva; Silvia Sacristán; M Isabel Pérez-Morgado; Matilde Salinas; M Elena Martín
Journal:  J Histochem Cytochem       Date:  2009-02-02       Impact factor: 2.479

3.  Sub-classification of low-grade cerebellar astrocytoma: is it clinically meaningful?

Authors:  Tine Bernhardtsen; Henning Laursen; Marie Bojsen-Møller; Flemming Gjerris
Journal:  Childs Nerv Syst       Date:  2003-09-30       Impact factor: 1.475

4.  Characterization of fenofibrate-mediated anti-proliferative pro-apoptotic effects on high-grade gliomas and anti-invasive effects on glioma stem cells.

Authors:  Emanuela Binello; Elisabetta Mormone; Luni Emdad; Harini Kothari; Isabelle M Germano
Journal:  J Neurooncol       Date:  2014-02-04       Impact factor: 4.130

5.  Clinical Correlation and Role of Cyclin D1 Expression in Glioblastoma Patients: A Study From North India.

Authors:  Mamta Jaiswal; Archana Tripathi; Dezy Singh; Arvind Kumar; Monika Singh; Neha Batra; Anil Verma
Journal:  Cureus       Date:  2022-02-17

6.  An Immunohistochemical Study of Cyclin D1 Expression in Astrocytic Tumors and its Correlation with Tumor Grade.

Authors:  Parvin Mahzouni; Fatemeh Taheri
Journal:  Iran J Pathol       Date:  2019-08-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.